Geneva, June 30 -- International Clinical Trials Registry received information related to the study (ACTRN12625000665437) titled 'Safety and Efficacy of FSD202 for the treatment of chronic pain associated with idiopathic MCAS (MCAD)' on June 24.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Primary Sponsor: FSD Pharma Australia Pty Ltd.
Condition:
Chronic Widespread Musculoskeletal Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome (Disorder)
Chronic Widespread Musculoskeletal Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome (Disorder)
Inflammatory and Immune System - Other inflammatory or immune syst...